Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

5,817 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Outstanding problems with response evaluation criteria in solid tumors (RECIST) in breast cancer.
Kimura M, Tominaga T. Kimura M, et al. Breast Cancer. 2002;9(2):153-9. doi: 10.1007/BF02967580. Breast Cancer. 2002. PMID: 12016395
[Efficacy of treatment with high-dose toremifene in patients with metastatic breast cancer resistant to aromatase inhibitor treatment].
Niikura N, Kimura M, Kobayashi Y, Asahara F, Hayashi K, Shibata S, Shintoku J. Niikura N, et al. Among authors: kimura m. Gan To Kagaku Ryoho. 2009 Jun;36(6):1013-6. Gan To Kagaku Ryoho. 2009. PMID: 19542727 Japanese.
Phase II Study of S-1 plus Trastuzumab for HER2-positive Metastatic Breast Cancer (GBCCSG-01).
Fujii T, Horiguchi J, Yanagita Y, Koibuchi Y, Ikeda F, Uchida N, Kimura M; GUNMA BREAST CLINICAL CONFERENCE STUDY GROUP (GBCCSG). Fujii T, et al. Among authors: kimura m. Anticancer Res. 2018 Feb;38(2):905-909. doi: 10.21873/anticanres.12301. Anticancer Res. 2018. PMID: 29374719 Clinical Trial.
Patients with BSA of <1.25 m(2) received a total of 80 mg of S-1, those with BSA ≥1.5 m(2) received 120 mg, and the remaining received 100 mg daily in two divided doses. ...
Patients with BSA of <1.25 m(2) received a total of 80 mg of S-1, those with BSA ≥1.5 m(2) received 120 mg, and the remaini …
Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment.
Niikura N, Kimura M, Iwamoto T, Hayashi N, Shintoku J, Saito Y, Suzuki Y, Tokuda Y. Niikura N, et al. Among authors: kimura m. Breast Cancer. 2013 Jan;20(1):67-74. doi: 10.1007/s12282-011-0310-5. Epub 2011 Nov 23. Breast Cancer. 2013. PMID: 22109640
A phase II study of S-1 in patients with metastatic breast cancer--a Japanese trial by the S-1 Cooperative Study Group, Breast Cancer Working Group.
Saek T, Takashima S, Sano M, Horikoshi N, Miura S, Shimizu S, Morimoto K, Kimura M, Aoyama H, Ota J, Noguchi S, Taguchi T. Saek T, et al. Among authors: kimura m. Breast Cancer. 2004;11(2):194-202. doi: 10.1007/BF02968301. Breast Cancer. 2004. PMID: 15550867 Clinical Trial.
BACKGROUND: S-1 is a newly developed novel oral dihydrouracil dehydrogenase inhibiting fluoropyrimidine drug consisting of 1 M tegafur (FT), 0.4 M 5-chloro-2, 4-dihydroxypyrimidine (gimeracil), and 1 M potassium oxonate (oteracil), with efficient antitumor ac …
BACKGROUND: S-1 is a newly developed novel oral dihydrouracil dehydrogenase inhibiting fluoropyrimidine drug consisting of 1 M tegafu …
[Early phase II dose-finding study of exemestane in postmenopausal patients with advanced/recurrent breast cancer].
Tabei T, Ogita M, Hirata K, Satomi S, Kimura M, Abe R, Morishita Y, Kimura M, Andou J, Higashi Y, Yoshino K, Tominaga K, Kajiwara T, Kitajima M, Koyanagi Y, Watanabe T, Yamaguchi S, Watanabe M, Toyama K, Kanda K, Kashiki Y, Miura S, Kobayashi Z, Aoyama H, Miyazaki I, Oka T, Koyama H, Kinoshita H, Monden M, Takai S, Yayoi E, Kobayashi T, Takatsuka Y, Kajiwara T, Sonoo H, Toge T, Takashima S, Nomura Y, Nagao K, Fujita Y. Tabei T, et al. Among authors: kimura m, kimura m. Gan To Kagaku Ryoho. 2002 Jul;29(7):1199-209. Gan To Kagaku Ryoho. 2002. PMID: 12146001 Clinical Trial. Japanese.
Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer.
Kimura M, Tominaga T, Kimijima I, Takatsuka Y, Takashima S, Nomura Y, Kasumi F, Yamaguchi A, Masuda N, Noguchi S, Eshima N. Kimura M, et al. Breast Cancer. 2014 May;21(3):275-83. doi: 10.1007/s12282-012-0394-6. Epub 2012 Sep 12. Breast Cancer. 2014. PMID: 22968626 Clinical Trial.
Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer.
Kusama M, Nomizu T, Aogi K, Yoshimoto M, Horikoshi N, Tabei T, Noguchi S, Miura S, Yoshimura N, Kimura M, Toyama K, Shin E. Kusama M, et al. Among authors: kimura m. Breast Cancer. 2010 Oct;17(4):233-40. doi: 10.1007/s12282-009-0137-5. Epub 2009 Jul 25. Breast Cancer. 2010. PMID: 19633909 Clinical Trial.
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
Kimura M, Tominaga T, Takatsuka Y, Toi M, Abe R, Koyama H, Takashima S, Nomura Y, Miura S, Kimijima I, Tashiro H, Ohashi Y; Adjuvant CEF Research Group for Breast Cancer. Kimura M, et al. Breast Cancer. 2010 Jul;17(3):190-8. doi: 10.1007/s12282-009-0132-x. Epub 2009 Jul 3. Breast Cancer. 2010. PMID: 19575284 Clinical Trial.
METHODS: A total of 294 patients with axillary node-positive primary breast cancer of STAGE I-IIIa were randomly assigned to either CEF [cyclophosphamide (CPA) 500 mg/m(2) i.v. days 1 and 8; epirubicin (EPI) 60 mg/m(2) i.v. day 1; and 5-fluorouracil (5-FU) 500 mg/ …
METHODS: A total of 294 patients with axillary node-positive primary breast cancer of STAGE I-IIIa were randomly assigned to either CEF [cyc …
Neoadjuvant paclitaxel for operable breast cancer: multicenter phase II trial with clinical outcomes.
Kimura M, Sano M, Fujimori M, Nakagomi H, Negishi T, Yanagita Y, Sato N. Kimura M, et al. Anticancer Res. 2008 Mar-Apr;28(2B):1239-44. Anticancer Res. 2008. PMID: 18505061 Clinical Trial.
5,817 results
Jump to page
Feedback